- Home
- AEAQ vs FENC Comparison
AEAQ vs FENC Comparison
Compare AEAQ & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$6.71
Company Overview
Basic Information| Metric | AEAQ | FENC |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.7M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | AEAQ | FENC |
|---|---|---|
| Price | $9.96 | $6.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 11.3K | ★ 133.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $5.65 |
| 52 Week High | $9.96 | $9.92 |
Technical Indicators
Market Signals| Indicator | AEAQ | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 45.69 |
| Support Level | $9.88 | $5.65 |
| Resistance Level | N/A | $8.09 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 100.00 | 56.36 |
Price Performance
Historical Comparison AEAQ
FENC
About AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share
Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.